227 related articles for article (PubMed ID: 17000468)
1. Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells.
Chiasson K; Daoust B; Levesque D; Martinoli MG
Neurotox Res; 2006 Aug; 10(1):31-42. PubMed ID: 17000468
[TBL] [Abstract][Full Text] [Related]
2. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.
Presgraves SP; Ahmed T; Borwege S; Joyce JN
Neurotox Res; 2004; 5(8):579-98. PubMed ID: 15111235
[TBL] [Abstract][Full Text] [Related]
3. Neuroprotective effect of estradiol and phytoestrogens on MPP+-induced cytotoxicity in neuronal PC12 cells.
Gélinas S; Martinoli MG
J Neurosci Res; 2002 Oct; 70(1):90-6. PubMed ID: 12237867
[TBL] [Abstract][Full Text] [Related]
4. Selective degeneration of dopaminergic neurons by MPP(+) and its rescue by D2 autoreceptors in Drosophila primary culture.
Wiemerslage L; Schultz BJ; Ganguly A; Lee D
J Neurochem; 2013 Aug; 126(4):529-40. PubMed ID: 23452092
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.
Collo G; Zanetti S; Missale C; Spano P
Eur J Neurosci; 2008 Oct; 28(7):1231-40. PubMed ID: 18973551
[TBL] [Abstract][Full Text] [Related]
6. A new approach to finding specific dopamine D4 receptor agonists.
Morishita H; Shibata K; Sakata N; Kita S; Katsuragi T
Eur J Pharmacol; 2005 Jun; 516(2):145-50. PubMed ID: 15922324
[TBL] [Abstract][Full Text] [Related]
7. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
[TBL] [Abstract][Full Text] [Related]
8. The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.
Altamirano-Espinoza AH; González-Hernández A; Manrique-Maldonado G; Marichal-Cancino BA; Ruiz-Salinas I; Villalón CM
Br J Pharmacol; 2013 Nov; 170(5):1102-11. PubMed ID: 24032529
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
Takashima H; Tsujihata M; Kishikawa M; Freed WJ
Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress.
Sawada H; Ibi M; Kihara T; Urushitani M; Akaike A; Kimura J; Shimohama S
Ann Neurol; 1998 Jul; 44(1):110-9. PubMed ID: 9667598
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade.
Kihara T; Shimohama S; Sawada H; Honda K; Nakamizo T; Kanki R; Yamashita H; Akaike A
J Neurosci Res; 2002 Nov; 70(3):274-82. PubMed ID: 12391586
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with the kappa opioid agonist U69593 enhances locomotor sensitization to the D2/D3 dopamine agonist quinpirole and alters dopamine D2 receptor and prodynorphin mRNA expression in rats.
Perreault ML; Graham D; Scattolon S; Wang Y; Szechtman H; Foster JA
Psychopharmacology (Berl); 2007 Nov; 194(4):485-96. PubMed ID: 17619861
[TBL] [Abstract][Full Text] [Related]
13. Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway.
Furuya KN; Thottassery JV; Schuetz EG; Sharif M; Schuetz JD
J Biol Chem; 1997 Apr; 272(17):11518-25. PubMed ID: 9111066
[TBL] [Abstract][Full Text] [Related]
14. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage.
Lim JH; Kim KM; Kim SW; Hwang O; Choi HJ
Pharmacol Res; 2008 May; 57(5):325-31. PubMed ID: 18455424
[TBL] [Abstract][Full Text] [Related]
15. Quinpirole-induced 50 kHz ultrasonic vocalization in the rat: role of D2 and D3 dopamine receptors.
Brudzynski SM; Komadoski M; St Pierre J
Behav Brain Res; 2012 Jan; 226(2):511-8. PubMed ID: 22015714
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells.
Qian JJ; Cheng YB; Yang YP; Mao CJ; Qin ZH; Li K; Liu CF
Neurosci Lett; 2008 Apr; 435(2):142-6. PubMed ID: 18342443
[TBL] [Abstract][Full Text] [Related]
17. Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function.
Huang Y; Qiu AW; Peng YP; Liu Y; Huang HW; Qiu YH
Neuro Endocrinol Lett; 2010; 31(6):782-91. PubMed ID: 21196914
[TBL] [Abstract][Full Text] [Related]
18. Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.
Zapata A; Kivell B; Han Y; Javitch JA; Bolan EA; Kuraguntla D; Jaligam V; Oz M; Jayanthi LD; Samuvel DJ; Ramamoorthy S; Shippenberg TS
J Biol Chem; 2007 Dec; 282(49):35842-54. PubMed ID: 17923483
[TBL] [Abstract][Full Text] [Related]
19. Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol.
Hashimoto T; Baba S; Ikeda H; Oda Y; Hashimoto K; Shimizu I
Eur J Pharmacol; 2018 Jul; 830():26-32. PubMed ID: 29684390
[TBL] [Abstract][Full Text] [Related]
20. Dopamine receptor subtypes colocalize in rat striatonigral neurons.
Surmeier DJ; Eberwine J; Wilson CJ; Cao Y; Stefani A; Kitai ST
Proc Natl Acad Sci U S A; 1992 Nov; 89(21):10178-82. PubMed ID: 1332033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
